Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 12/20 | 0.56 |
| ▸ | PPARG | P37231 | 10/20 | 0.56 |
| ▸ | PPARD | Q03181 | 4/20 | 0.56 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.55 |
| ▸ | SRR | Q9GZT4 | 4/20 | 0.51 |
| ▸ | ESR1 | P03372 | 2/20 | 0.51 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.51 |
| ▸ | PSAT1 | Q9Y617 | 2/20 | 0.50 |
| ▸ | LDHA | P00338 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4941128 | 1.00 | PPARA (0.56) | PPARAPPARGPPARDSLC7A5SRR | |
| SCHEMBL3466702 | 1.00 | PPARA (0.56) | PPARAPPARGPPARDSLC7A5SRR | |
| SCHEMBL5607495 | 0.98 | PPARA (0.55) | PPARAPPARGPPARDSLC7A5SRR | |
| SCHEMBL5607756 | 0.98 | PPARA (0.55) | PPARAPPARGPPARDSLC7A5SRR | |
| Rubidium SCHEMBL5607497 | 0.98 | PPARA (0.55) | PPARAPPARGPPARDSLC7A5SRR | |
| SCHEMBL5607096 | 0.98 | PPARA (0.55) | PPARAPPARGPPARDSLC7A5SRR | |
| SCHEMBL5606722 | 0.98 | PPARA (0.55) | PPARAPPARGPPARDSLC7A5SRR | |
| SCHEMBL4811729 | 0.98 | PPARA (0.55) | PPARAPPARGPPARDSLC7A5SRR | |
| Ammonia Solution, Strong SCHEMBL5606748 | 0.98 | PPARA (0.55) | PPARAPPARGPPARDSLC7A5SRR | |
| SCHEMBL5606989 | 0.98 | PPARA (0.55) | PPARAPPARGPPARDSLC7A5SRR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7427691-B2 | Resolution of p-hydroxyphenyl-2-alkoxypropionic acids | DEGUSSA GMBH (DE) | 2008-09-23 | — | — | US | claimed |
| US-20230399297-A1 | Novel Glutamine Analogs | JACOBIO PHARMACEUTICALS CO., LTD (CN) | 2023-12-14 | — | — | US | disclosed |
| US-20230399297-A1 | Novel Glutamine Analogs | JACOBIO PHARMACEUTICALS CO., LTD (CN) | 2023-12-14 | — | — | US | disclosed |
| WO-2022078416-A1 | NOVEL GLUTAMINE ANALOGS | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2022-04-21 | — | — | WO | disclosed |
| EP-1801093-B1 | Process for the Preparation of enantiomer-enriched 2-Alkoxy-3-Phenyl-Propionic Acid | SALTIGO GMBH (DE) | 2009-03-18 | — | — | EP | disclosed |
| US-20090029429-A1 | Process for Producing Optically Active 2-Substituent-Oxy-3-(4-Substituent-Oxyphenyl) Propionic Acid Derivative | KANEKA CORPORATION (JP) | 2009-01-29 | — | — | US | disclosed |
| US-7429676-B2 | Process for preparing enantiomerically enriched 2-alkoxy-3-phenylpropionic acids | SALTIGO GMBH (DE) | 2008-09-30 | — | — | US | disclosed |
| US-7429676-B2 | Process for preparing enantiomerically enriched 2-alkoxy-3-phenylpropionic acids | SALTIGO GMBH (DE) | 2008-09-30 | — | — | US | disclosed |
| US-7427691-B2 | Resolution of p-hydroxyphenyl-2-alkoxypropionic acids | DEGUSSA GMBH (DE) | 2008-09-23 | — | — | US | disclosed |
| US-20080064897-A1 | Resolution of P-Hydroxyphenyl-2-Alkoxypropionic Acids | GEGUSSA AG (DE) | 2008-03-13 | — | — | US | disclosed |
| US-20060111406-A1 | Amide linker peroxisome proliferator activated receptor modulators | ELI LILLY AND COMPANY (US) | 2006-05-25 | — | — | US | disclosed |
| WO-2006007976-A1 | RESOLUTION OF P-HYDROXYPHENYL-2-ALKOXYPROPIONIC ACIDS | DEGUSSA AG (DE) | 2006-01-26 | — | — | WO | disclosed |
| CN-1662487-A | Amide linker peroxisome proliferator-activated receptor modulators | LILLY CO ELI (US) | 2005-08-31 | — | — | CN | disclosed |
| EP-1517882-A1 | AMIDE LINKER PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-03-30 | — | — | EP | disclosed |
| US-20050020684-A1 | Modulators of peroxisome proliferator activated receptors | ELI LILLY AND COMPANY | 2005-01-27 | — | — | US | disclosed |
| CN-1543451-A | Receptor modulators activated by peroxizonal proliferators (ppar) | — | 2004-11-03 | — | — | CN | disclosed |
| WO-2004000789-A9 | AMIDE LINKER PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR MODULATORS | LILLY CO ELI (US) | 2004-03-11 | — | — | WO | disclosed |
| EP-1392637-A2 | MODULATORS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS | ELI LILLY AND COMPANY (US) | 2004-03-03 | — | — | EP | disclosed |
| WO-2004000789-A1 | AMIDE LINKER PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2003-12-31 | — | — | WO | disclosed |
| WO-2002100813-A2 | MODULATORS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS | ELI LILLY AND COMPANY (US) | 2002-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230399297-A1 | Novel Glutamine Analogs | GLUL, GATD3, GLS | PPARA 1857/4885PPARG 1211/4885PPARD 1270/4885 |
| US-20050020684-A1 | Modulators of peroxisome proliferator activated receptors | NCOA4, PPARG, PPARA | PPARA 3/4885PPARG 2/4885PPARD 7/4885 |
| US-20060111406-A1 | Amide linker peroxisome proliferator activated receptor modulators | PPARG, PPARA, PPARD | PPARA 2/4885PPARG 1/4885PPARD 3/4885 |
| US-20080064897-A1 | Resolution of P-Hydroxyphenyl-2-Alkoxypropionic Acids | PAH, GRHPR, NPPA | PPARA 1931/4885PPARG 2184/4885PPARD 2162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.